TDP-43 Conference Marks Concerted Effort to Finally Snag Biomarkers. Add To My AlzForum; 30 Jun 2025. Steps Forward: Immunoassays for cryptic HDGFL2 flag TDP-43 proteinopathy in diverse disorders.

A documentary of country legend Glen Campbell's life and “Goodbye Tour” following his diagnosis of Alzheimer's ...

Species: Mouse Genes: MAPT Mutations: MAPT P301L Modification: MAPT: Transgenic Disease Relevance: Alzheimer's Disease, Frontotemporal Dementia Strain Name: Thy1-hTau.P301L Genetic Background: FVB/N ...

Overview. Pathogenicity: Alzheimer's Disease : Pathogenic, Cerebral Amyloid Angiopathy, Down's Syndrome ACMG/AMP Pathogenicity Criteria: PS1, PS2, PS3, PS4, PM1 Clinical Phenotype Studied: Alzheimer's ...

22 Jul 2022. The Alzheimer’s field was rocked this week by allegations against Sylvain Lesné at the University of Minnesota, Minneapolis. Lesné stands accused of manipulating data images in multiple ...

Dennis Selkoe Co-Director, Brigham and Women's Hospital's Ann Romney Center for Neurologic Diseases; Posted: 21 Mar 2019 This morning’s news that an interim analysis by Biogen of their Phase 3 ...

Ivonne Suridjan Roche; Posted: 06 Oct 2021 This publication references Aβ 42/40 prototype assays currently in feasibility testing as potential blood-based biomarkers for AD within Roche Diagnostics; ...

Li-Huei Tsai, Massachusetts Institute of Technology, Boston, and colleagues some years ago turned light and sound into a therapy.They called it GENUS, short for gamma entrainment using sensory stimuli ...

David Holtzman Washington University; Posted: 27 Jul 2018 The new data clearly showed that the anti-Aβ antibody BAN2401 was able to significantly remove amyloid from brain, as quantified by ...

04 May 2023. Score another one for amyloid immunotherapy. The anti-pyroglutamated amyloid antibody donanemab has posted positive top-line results in the Phase 3 Trailblazer-Alz2 study, according to an ...

20 Jan 2022. After months of uncertainty, the hammer fell for Biogen: In a draft decision released January 11, the Centers for Medicare and Medicaid Services proposed to cover the anti-amyloid ...

28 Sep 2022. Eisai and Biogen yesterday announced positive topline results from the Phase 3 Clarity trial of their anti-amyloid antibody lecanemab.The drug slowed decline on the primary endpoint, ...